newsfilter
← Latest News
GlobeNewswire·

CytoDyn Engages Leading CRO For Phase II Inflammation Trial

VANCOUVER, Washington, Aug. 23, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB:CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple